Clinical Trial Update: A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN) [Phase 3]

View source ↗

Summary

Phase 3 trial of TAK-771 in Japanese participants with CIDP and MMN completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyradiculoneuropathy
• Multifocal Motor Neuropathy

Drugs mentioned

• TAK-771

Snippet

Sponsor: Takeda | Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Multifocal Motor Neuropathy (MMN) | Phase 3 | Status: COMPLETED | Results posted: 2025-03-18